More than one-third of advanced non-small-cell lung cancer patients do not receive immunochemotherapy due to intolerance.

Chihiro Ando,Eiki Ichihara,Toshihide Yokoyama,Koji Inoue,Tomoki Tamura,Keiichi Fujiwara,Naohiro Oda,Hirohisa Kano,Daizo Kishino,Kazuhiko Watanabe,Masaaki Inoue,Nobuaki Ochi,Fumie Onishi,Hirohisa Ichikawa,Hiroshi Kobe,Sayaka Tachibana,Katsuyuki Hotta,Yoshinobu Maeda,Katsuyuki Kiura

Journal of cancer research and clinical oncology（2022）

引用 0|浏览11

暂无评分

摘要

Our results revealed that a substantial proportion of advanced NSCLC patients did not benefit from ICI + chemotherapy due to intolerance. As treatments for NSCLC are moving toward combinations for greater efficacy, their feasibility in clinical practice must be taken into consideration.

查看译文

关键词

Clinical practice,Combination therapy,Feasibility,Immune checkpoint inhibitor,Non-small-cell lung cancer

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要